Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
220 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Nephropathy - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Diabetic Nephropathy - Pipeline Review, H2 2016', provides an overview of the Diabetic Nephropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects - The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Diabetic Nephropathy Overview 9 Therapeutics Development 10 Pipeline Products for Diabetic Nephropathy - Overview 10 Pipeline Products for Diabetic Nephropathy - Comparative Analysis 11 Diabetic Nephropathy - Therapeutics under Development by Companies 12 Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes 15 Diabetic Nephropathy - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Diabetic Nephropathy - Products under Development by Companies 20 Diabetic Nephropathy - Products under Investigation by Universities/Institutes 23 Diabetic Nephropathy - Companies Involved in Therapeutics Development 24 AbbVie Inc 24 Ampio Pharmaceuticals, Inc. 25 Antisense Therapeutics Limited 26 Araim Pharmaceuticals, Inc. 27 Arena Pharmaceuticals, Inc. 28 Astellas Pharma Inc. 29 AstraZeneca Plc 30 Bayer AG 31 BiOrion Technologies B.V. 32 Boehringer Ingelheim GmbH 33 Cellmid Limited 34 ChemoCentryx, Inc. 35 CSL Limited 36 Daiichi Sankyo Company, Limited 37 Dimerix Bioscience Pty Ltd 38 Dong Wha Pharma Co., Ltd. 39 Dynamis Therapeutics, Inc. 40 Eli Lilly and Company 41 Galectin Therapeutics, Inc. 42 GenKyoTex S.A. 43 Gilead Sciences, Inc. 44 GlaxoSmithKline Plc 45 Glucox Biotech AB 46 GNI Group Ltd. 47 Islet Sciences, Inc. 48 Jenrin Discovery, Inc. 49 Johnson & Johnson 50 Mallinckrodt Plc 51 Mesoblast Limited 52 Mitsubishi Tanabe Pharma Corporation 53 MorphoSys AG 54 Noxxon Pharma AG 55 Omeros Corporation 56 Otsuka Holdings Co., Ltd. 57 PhytoHealth Corporation 58 ProMetic Life Sciences Inc. 59 Serodus ASA 60 Takeda Pharmaceutical Company Limited 61 Theravance Biopharma, Inc. 62 Tobira Therapeutics, Inc. 63 Vascular Pharmaceuticals, Inc. 64 Vicore Pharma AB 65 Diabetic Nephropathy - Therapeutics Assessment 66 Assessment by Monotherapy Products 66 Assessment by Target 67 Assessment by Mechanism of Action 70 Assessment by Route of Administration 74 Assessment by Molecule Type 76 Drug Profiles 78 11-RVIVIT - Drug Profile 78 A-717 - Drug Profile 79 Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 80 APD-371 - Drug Profile 81 APX-115 - Drug Profile 82 ASP-8232 - Drug Profile 83 ATL-1103 - Drug Profile 84 atrasentan hydrochloride - Drug Profile 91 baricitinib - Drug Profile 93 BI-703704 - Drug Profile 100 BOT-191 - Drug Profile 101 C-21 - Drug Profile 102 canagliflozin - Drug Profile 104 CCX-140 - Drug Profile 111 cenicriviroc mesylate - Drug Profile 115 cibinetide - Drug Profile 122 corticotropin - Drug Profile 125 CS-3150 - Drug Profile 127 CSL-346 - Drug Profile 129 Cyndacel-M - Drug Profile 130 danazol - Drug Profile 131 DMX-250 - Drug Profile 135 DT-23552 - Drug Profile 136 DW-1029M - Drug Profile 137 DYN-12 - Drug Profile 138 emapticap pegol - Drug Profile 140 finerenone - Drug Profile 142 GKT-136901 - Drug Profile 144 GKT-831 - Drug Profile 145 GRMD-02 - Drug Profile 148 GW-610742 - Drug Profile 158 IP-9 - Drug Profile 159 JD-5037 - Drug Profile 160 JNJ-39933673 - Drug Profile 161 MG-132 - Drug Profile 162 Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 163 MOR-107 - Drug Profile 165 MPC-300IV - Drug Profile 166 MT-3995 - Drug Profile 170 Nephrilin - Drug Profile 171 Orbcel-M - Drug Profile 172 oxypurinol - Drug Profile 173 PBI-4050 - Drug Profile 174 PBI-4547 - Drug Profile 179 PHN-033 - Drug Profile 180 pirfenidone - Drug Profile 181 probucol - Drug Profile 182 selonsertib - Drug Profile 183 SER-150 - Drug Profile 184 Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile 187 Small Molecules for Diabetic Nephropathy - Drug Profile 188 Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 189 Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 190 SP-20202 - Drug Profile 192 TAK-272 - Drug Profile 193 TBE-31 - Drug Profile 194 TD-0714 - Drug Profile 195 VPI-2690B - Drug Profile 197 VS-105 - Drug Profile 198 XRX-108 - Drug Profile 199 XRX-221 - Drug Profile 200 Diabetic Nephropathy - Dormant Projects 201 Diabetic Nephropathy - Discontinued Products 204 Diabetic Nephropathy - Product Development Milestones 205 Featured News & Press Releases 205 Appendix 215 Methodology 215 Coverage 215 Secondary Research 215 Primary Research 215 Expert Panel Validation 215 Contact Us 215 Disclaimer 216
List of Tables
Number of Products under Development for Diabetic Nephropathy, H2 2016 14 Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Number of Products under Development by Companies, H2 2016 (Contd..1) 17 Number of Products under Development by Companies, H2 2016 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H2 2016 19 Comparative Analysis by Late Stage Development, H2 2016 20 Comparative Analysis by Clinical Stage Development, H2 2016 21 Comparative Analysis by Early Stage Development, H2 2016 22 Comparative Analysis by Unknown Stage Development, H2 2016 23 Products under Development by Companies, H2 2016 24 Products under Development by Companies, H2 2016 (Contd..1) 25 Products under Development by Companies, H2 2016 (Contd..2) 26 Products under Investigation by Universities/Institutes, H2 2016 27 Diabetic Nephropathy - Pipeline by AbbVie Inc, H2 2016 28 Diabetic Nephropathy - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 29 Diabetic Nephropathy - Pipeline by Antisense Therapeutics Limited, H2 2016 30 Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 31 Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 32 Diabetic Nephropathy - Pipeline by Astellas Pharma Inc., H2 2016 33 Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H2 2016 34 Diabetic Nephropathy - Pipeline by Bayer AG, H2 2016 35 Diabetic Nephropathy - Pipeline by BiOrion Technologies B.V., H2 2016 36 Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H2 2016 37 Diabetic Nephropathy - Pipeline by Cellmid Limited, H2 2016 38 Diabetic Nephropathy - Pipeline by ChemoCentryx, Inc., H2 2016 39 Diabetic Nephropathy - Pipeline by CSL Limited, H2 2016 40 Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 41 Diabetic Nephropathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 42 Diabetic Nephropathy - Pipeline by Dong Wha Pharma Co., Ltd., H2 2016 43 Diabetic Nephropathy - Pipeline by Dynamis Therapeutics, Inc., H2 2016 44 Diabetic Nephropathy - Pipeline by Eli Lilly and Company, H2 2016 45 Diabetic Nephropathy - Pipeline by Galectin Therapeutics, Inc., H2 2016 46 Diabetic Nephropathy - Pipeline by GenKyoTex S.A., H2 2016 47 Diabetic Nephropathy - Pipeline by Gilead Sciences, Inc., H2 2016 48 Diabetic Nephropathy - Pipeline by GlaxoSmithKline Plc, H2 2016 49 Diabetic Nephropathy - Pipeline by Glucox Biotech AB, H2 2016 50 Diabetic Nephropathy - Pipeline by GNI Group Ltd., H2 2016 51 Diabetic Nephropathy - Pipeline by Islet Sciences, Inc., H2 2016 52 Diabetic Nephropathy - Pipeline by Jenrin Discovery, Inc., H2 2016 53 Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2016 54 Diabetic Nephropathy - Pipeline by Mallinckrodt Plc, H2 2016 55 Diabetic Nephropathy - Pipeline by Mesoblast Limited, H2 2016 56 Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 57 Diabetic Nephropathy - Pipeline by MorphoSys AG, H2 2016 58 Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2016 59 Diabetic Nephropathy - Pipeline by Omeros Corporation, H2 2016 60 Diabetic Nephropathy - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 61 Diabetic Nephropathy - Pipeline by PhytoHealth Corporation, H2 2016 62 Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc., H2 2016 63 Diabetic Nephropathy - Pipeline by Serodus ASA, H2 2016 64 Diabetic Nephropathy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 65 Diabetic Nephropathy - Pipeline by Theravance Biopharma, Inc., H2 2016 66 Diabetic Nephropathy - Pipeline by Tobira Therapeutics, Inc., H2 2016 67 Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals, Inc., H2 2016 68 Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H2 2016 69 Assessment by Monotherapy Products, H2 2016 70 Number of Products by Stage and Target, H2 2016 72 Number of Products by Stage and Mechanism of Action, H2 2016 75 Number of Products by Stage and Route of Administration, H2 2016 79 Number of Products by Stage and Molecule Type, H2 2016 81 Diabetic Nephropathy - Dormant Projects, H2 2016 205 Diabetic Nephropathy - Dormant Projects (Contd..1), H2 2016 206 Diabetic Nephropathy - Dormant Projects (Contd..2), H2 2016 207 Diabetic Nephropathy - Discontinued Products, H2 2016 208
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
